9 articles

  1. Gilead’s HCV drug sofosbuvir approved by the FDA but accessible for how many? Press Release – December 9 / Bangkok – Paris – Basel – London – New York

    On December 6, the U.S. Food and Drug Administration approved Gilead’s sofosbuvir (Sovaldi), an oral medication for the treatment of hepatitis C virus (HCV). Sofosbuvir and other direct-acting antivirals (DAAs) coming out of the drug development pipeline are more potent, have fewer side effects, (...) More

  2. AIDS 2014 : Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug "HCV drugs are priced out of reach and out of control", Michel Sidibé, UNAIDS

  3. Equitable access to HCV drugs